The stock of Jupiter Neurosciences Inc (JUNS) has seen a 9.77% increase in the past week, with a 43.89% gain in the past month, and a 35.03% flourish in the past quarter. The volatility ratio for the week is 9.08%, and the volatility levels for the past 30 days are at 8.06% for JUNS. The simple moving average for the past 20 days is 28.48% for JUNS’s stock, with a -68.24% simple moving average for the past 200 days.
Is It Worth Investing in Jupiter Neurosciences Inc (NASDAQ: JUNS) Right Now?
Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for JUNS is 14.08M, and currently, shorts hold a 0.80% of that float. The average trading volume for JUNS on June 10, 2025 was 108.19K shares.
JUNS) stock’s latest price update
The stock of Jupiter Neurosciences Inc (NASDAQ: JUNS) has increased by 15.20 when compared to last closing price of 0.78.Despite this, the company has seen a gain of 9.77% in its stock price over the last five trading days. globenewswire.com reported 2025-02-04 that Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product launch later this year, which is expected to generate near-term revenues while the Company advances its clinical trials.
JUNS Trading at 38.10% from the 50-Day Moving Average
After a stumble in the market that brought JUNS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.39% of loss for the given period.
#####
#####
Stock Fundamentals for JUNS
The total capital return value is set at -1.32.
Based on Jupiter Neurosciences Inc (JUNS), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -23.89. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -20.97.
Currently, EBITDA for the company is -2.19 million with net debt to EBITDA at 0.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.91.
Conclusion
In conclusion, Jupiter Neurosciences Inc (JUNS) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
